Interpretation and Enlightenment of Expert Consensus on Clinical Application of Yifei Zhike Capsules
10.13422/j.cnki.syfjx.20261492
- VernacularTitle:《益肺止咳胶囊临床应用专家共识》解读
- Author:
Wenye FENG
1
;
Hongchun ZHANG
2
;
Xuefeng YU
3
;
Weiwei GUO
4
;
Chengjun BAN
5
;
Zhifei WANG
1
;
Yuanyuan LI
1
;
Yingjie ZHI
1
;
Jing REN
6
;
Xin CUI
1
;
Yanming XIE
1
Author Information
1. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. China-Japan Friendship Hospital，Beijing 100029，China
3. The Second Affiliated Hospital ofLiaoning University of Traditional Chinese Medicine，Shenyang 110034，China
4. Qiandongnan Institute of Ethnic Medicine and Affiliated Miao Hospital，Guizhou 556099，China
5. Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 101121，China
6. Haidian Third Retired Cadre Sanatorium of Beijing Garrison，Beijing 100840，China
- Publication Type:Journal Article
- Keywords:
Yifei Zhike capsules;
Miao medicine;
expert consensus;
clinical application;
interpretation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(23):178-185
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo interpret the main contents of the Expert Consensus on Clinical Application of Yifei Zhike Capsules （hereinafter referred to as the Consensus）， analyze its evidence basis， and explore future research directions， thus providing a reference for rational drug use in clinical practice. MethodsThe core contents of the Consensus are summarized. Focusing on clinical issues， this paper summarizes the recommendations and consensus suggestions in the Consensus and explains them from aspects such as indications， key advantages， usage and dosage， combined medication， contraindications， precautions， and safety. ResultsThe Consensus clearly states that Yifei Zhike capsules can be used for acute or chronic bronchitis， pulmonary tuberculosis and other respiratory system diseases. It for the first time proposes that the applicable TCM syndrome of Yifei Zhike capsules is Qi-Yin deficiency together with combined phlegm and stasis. For different diseases， the Consensus provides specific usage instructions， dosage， and treatment course recommendations， supplementing the contents not covered in the drug instructions. In terms of combined medication， the Consensus emphasizes the principle of using this drug in combination with standardized chemotherapy regimens or conventional Western medicines and the applicability for the treatment of pulmonary tuberculosis and moderate to severe acute or chronic bronchitis. In terms of safety， the Consensus proposes methods for identifying common adverse reactions， drug contraindications， and precautions based on a review of the existing data and preliminarily builds a risk management framework. However， the evidence on which the Consensus is based are mostly early studies， with small sample sizes， which result in the low evidence grades （mainly C and D） of some recommendations. ConclusionThe Consensus provides specific guidance for the clinical use of Yifei Zhike capsules. However， due to the limited quality of the existing research evidence， more high-quality clinical studies are needed in the future to further verify its efficacy， safety， and explore its broader application prospects.
